
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-11-01-2007
- Volume 19
- Issue 11
Couch potato drugs
Some people claim the statins are so effective and that their cholesterol has dropped to a point where they can "supersize" their burger and chips every time they visit a fast food outlet
Unless you've had your head buried in the sand for last 10 years, you'll know that there is a dearth of blockbuster drugs in the pipeline. But many manufacturers are now switching their attention to so called lifestyle drugs as they seek to cash in on "behavioural" disorders. In today's competitive market, there are enough people in developed countries willing to pay a premium price for such treatments, but is it really doing the patients any good? Well in some cases, no.
Gurminder Marwaha
Take, for example, statins. These form a class of hypolipidemic agents, used as pharmaceutical agents to lower cholesterol levels in people with, or at risk of, cardiovascular disease. Of course, your medical practioner should encourage a cholesterol-lowering diet and increased exercise before proceeding with a course of statins.
And herein lies the crux of the problem, because along with global warming and taxes, one thing is certain — people in the western world are getting fat. Not just "a little more around the middle", but dangerously obese. Today's lifestyle does little to promote eating healthy and exercising, and does plenty to advocate junk food, ready meals, video games and other things associated with the couch potato culture. Perhaps drug manufacturers have been too effective, because now you can simply pop an over-the-counter pill from the comfort of your sofa, which will lower your cholesterol within a week of treatment. Some people claim the statins are so effective and that their cholesterol has dropped to a point where they can "supersize" their burger and chips every time they visit a fast food outlet.
The danger is, of course, that you are doing yourself more harm than good by taking such medication while continuing to eat badly and not exercise. Perhaps manufacturers and doctors need to highlight the associated behavioural issues more when promoting their particular brand of lifestyle drug. Then again, have we reached the point where people would rather take a tablet than go for a jog and eat a balanced diet? A survey by the British Heart Foundation (
Gurminder Marwaha
Articles in this issue
about 18 years ago
PAT — a place for separation scienceabout 18 years ago
Preventive maintenance strategies for the pharmaceutical industryabout 18 years ago
Packaged solutions for flexible productionabout 18 years ago
Pandemics to polio — challenges in vaccine manufactureabout 18 years ago
Monitoring processing-induced crystallinity changesabout 18 years ago
Analysis of adrenoreceptor agonists and antagonistsabout 18 years ago
USP faces up to analytical realityabout 18 years ago
Ensuring virus safety for biological productsNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





